Orasure Technologies INC

OraSure Technologies' subsidiary DNA Genotek announced FDA clearance for its Colli-PeeDx Urine Collection Kit, enabling at-home self-collection for specific STI tests on Roche diagnostic systems.

OraSure Technologies announced its first quarter 2026 financial results, with total net revenues of $27.9 million, slightly below the prior year but above the midpoint of guidance, and improved gross margins.

OraSure Technologies has entered into a cooperation agreement with Altai Capital, resulting in a new board appointment and a commitment to declassify the board.

OraSure Technologies issued a presentation to counter Altai Capital Management's claims, highlighting its strategic execution, financial performance, and strong corporate governance.

OraSure Technologies announces the resignation of Dr. David J. Shulkin from its Board of Directors, effective March 2, 2026.

OraSure Technologies reported a 29% decrease in Q4 2025 total net revenues to $26.8 million, while submitting two key product applications to the FDA for regulatory clearance.

OraSure Technologies reports a net loss of $22.4 million for Q1 2026 as the company navigates a transition in its product portfolio and cost structure.

OraSure Technologies, Inc. reported a significant increase in net loss and a substantial revenue decline for the three and nine months ended September 30, 2025, driven by reduced demand for COVID-19 tests and lower international HIV revenues, despite strategic acquisitions and cost-cutting measures.

OraSure Technologies, Inc. reported a significant decrease in net revenues and a substantial increase in net loss for the second quarter and first half of 2025, driven by reduced COVID-19 testing demand and strategic business exits.

OraSure Technologies' Q1 2025 results reveal a significant revenue decrease primarily due to reduced COVID-19 test sales, alongside strategic adjustments including workforce reductions and business line discontinuations.

OraSure Technologies experienced a significant revenue decrease in Q3 2024, driven by reduced COVID-19 testing demand and strategic business restructuring.

OraSure Technologies experienced a significant revenue decrease in the second quarter of 2024, driven by reduced COVID-19 testing demand and strategic business restructuring.

OraSure Technologies reports a net loss for 2024, announces the acquisition of Sherlock Biosciences, and details strategic shifts in its business operations.

OraSure Technologies reports a profitable 2023, driven by InteliSwab sales and cost management, while also detailing risks and future strategies in its annual 10-K filing.

Orasure Technologies Director Steven Kyle Boyd acquired 3,666 shares of common stock on June 26, 2026, as part of a compensation plan.

OraSure Technologies Director Robert W. McMahon was granted 46,106 restricted shares, increasing his beneficial ownership to 123,137 shares.

OraSure Technologies Director Nancy J. Gagliano received a grant of 46,106 restricted shares as part of the company's annual equity compensation plan.

Director Lelio Marmora was granted 46,106 restricted shares of OraSure Technologies, increasing his total ownership to 148,460 shares.

Director John P. Kenny was granted 46,106 restricted shares of OraSure Technologies, increasing his total ownership to over 200,000 shares.

OraSure Technologies Director John D. Bertrand has been granted 46,106 restricted shares as part of the company's annual equity compensation plan.

OraSure Technologies announces its 2026 Annual Meeting of Stockholders, focusing on board declassification and executive compensation.

OraSure Technologies confirmed receipt of director nominations from Altai Capital for its 2026 Annual Meeting, with the Board planning to review and make recommendations.

OraSure Technologies confirmed Altai Capital's intent to nominate two director candidates for the 2026 Annual Meeting, stating its commitment to shareholder value and board independence.

OraSure Technologies, Inc. announces its 2025 Annual Meeting of Stockholders to be held on May 14, 2025, with voting open until May 13, 2025, covering director elections, auditor ratification, executive compensation, and stock award plan amendments.

OraSure Technologies is asking stockholders to approve an amendment to its stock award plan to increase the number of shares available for grant, aiming to attract and retain qualified personnel.

OraSure Technologies, Inc. announces its 2024 Annual Meeting of Stockholders to be held virtually on May 14, 2024, with several key proposals up for vote.

OraSure Technologies and Altai Capital Management have entered into a cooperation agreement, leading to Altai Capital withdrawing its director nominations and agreeing to support the declassification of OraSure's board.

Altai Capital Management, a 5% shareholder, has launched a proxy contest to elect two new directors to OraSure Technologies' board, citing chronic underperformance and misaligned management incentives.

Altai Capital Management, holding a 5.21% stake in OraSure Technologies, has nominated two directors and proposed board declassification for the 2026 Annual Meeting.

Activist investor Altai Capital Management, holding 5.2% of OraSure Technologies, announced its intention to nominate two directors to the board, citing a 'failing strategy' and 'destroyed shareholder value'.

Altai Capital Management and its affiliates have disclosed a 5.13% beneficial ownership stake in OraSure Technologies Inc., acquired for investment purposes.

Private Management Group, Inc. has increased its beneficial ownership of Orasure Technologies Inc. common stock to 5.5%, holding 3,797,682 shares.

Vanguard Capital Management has reported beneficial ownership of 5.04% of OraSure Technologies Inc.'s common stock as of March 31, 2026.

Gagnon Securities LLC, Gagnon Advisors, LLC, and Neil Gagnon collectively report beneficial ownership of 5.4% of Orasure Technologies Inc. common stock.

The Vanguard Group reports 0% beneficial ownership in OraSure Technologies Inc. following an internal realignment.

Gagnon Securities LLC, Gagnon Advisors, LLC, and Neil Gagnon have collectively reported a 4.9% beneficial ownership stake in Orasure Technologies, Inc. common stock.

Neil Gagnon and affiliated entities, Gagnon Securities LLC and Gagnon Advisors, LLC, have reported a combined beneficial ownership of 5.0% in OraSure Technologies Inc. common stock.